Orexo AB (publ) (0H19.IL)
IOB · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 5.00 (-1.19%) as of
Key statistics
- Market cap
- 172.08M
- EPS (TTM)
- -5.6600
- 52-week range
- 5.0000 – 35.5000
- Beta
- 0.67
- Revenue (TTM)
- 633.8M
- Profit margin
- -30.72%
- Volume
- 616.00
About Orexo AB (publ)
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Uppsala, Sweden
- Employees
- 120
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.